Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00961493 · ClinicalTrials.gov registry record · NA
RCT of an Acceptance-based Behavior Therapy for GAD
A NA study, sponsored by University of Massachusetts, Boston.
- Completed
- Registry status
- NA
- Development phase
- 81
- Enrollment target
NCT00961493: Completed NA study, sponsored by University of Massachusetts, Boston.
NCT00961493 is a NA study that has completed, run by University of Massachusetts, Boston. The registered enrollment target is 81 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00961493, a NA study, has completed, sponsored by University of Massachusetts, Boston.
- COMPLETED
- Registry status
- NA
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether acceptance-based behavior therapy for GAD results in greater symptom reduction and increased quality of life than applied relaxation.
Interventions
- BEHAVIORAL Applied relaxation
- BEHAVIORAL Acceptance based behavioral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2007-03 |
| Est. Completion | 2013-02 |
| Phase | NA |
What the finished NCT00961493 record still lists
NCT00961493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Applied relaxation is the first listed.
NCT00961493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00961493 about?
NCT00961493 is a clinical study titled "RCT of an Acceptance-based Behavior Therapy for GAD". The purpose of this study is to determine whether acceptance-based behavior therapy for GAD results in greater symptom reduction and increased quality of life than applied relaxation.
What is the current status of trial NCT00961493?
This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2007-03. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00961493?
The interventions under investigation include: Applied relaxation (BEHAVIORAL), Acceptance based behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00961493?
This trial is sponsored by University of Massachusetts, Boston, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00961493's enrollment target sits among peer trials
81 992nd of 2000 higher than 1,007 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia